TopFunds

Boston Scientific Corporation

NYSE: BSX

Stock price

64.61 USD

(+58.13%) 5 years

Medical - Devices

Financial Performance

Share

5Y price score: 84

Help
The price score is a basic measure of the stock's performance
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.

10Y return: 232%

DATE RANGE:

US$ Per
Share

  • Earnings per share

  • Free cash flow per share

  • Stock price

By default your notes are visible only to you.

60.5

52-week range

109.5

64.61

Your model inputs

Required return / cost of capital
FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

3.8 %

Dividend Yield TTM

-

Market cap $

$ 96,022

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

33.5

Price / Book TTM

4

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

0.6

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(31.4) %

58.1 %

232 %

Free cash flow per share growth

37.5 %

206.3 %

830 %

Earnings per share growth

55.2 %

2,489.2 %

1,177.8 %

Founded: 1,979

Employees: 53,000

Business Summary: Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Financials

all figures in USD Millions except per share data

Periods:

View:

Forecast:

Help

Averages

based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.

Analysts

Average Revenue and Net Income forecast estimates from analysts who cover the stock.

Custom

you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.

Actual
10 year gagr
Estimated
Projected
Fiscal
FISCAL PERIOD END DATES
01Earnings per share
Help
Diluted EPS
02FCF per share
03Dividends per share
Help
Adjusted for splits
04Dividends payout, %
05Revenue
06ㅤ% Change
07Net Income
08ㅤ% Margin
09CFO
10ㅤ% Of revenue
11CAPEX
12ㅤ% Change
13FCFF
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities (09) – Capital Expenditures (11)
14Total assets
15ㅤ% Change
16Total liabilities
17ㅤ% Of assets
18Shareholders Equity
19Net Debt
20Shares Outstanding
Help
Diluted Weighted-average Shares Outstanding
21ㅤ% Change
22ROA
23ROE
24Interest coverage
25Dividend Yield
26P/E Ratio
27Stock price range
28Market Cap
Help
End of Period Market Cap
29FCF Yield
30Average stock price
31 CEO
Fair Value Reference Estimate

  • Increase

  • Decrease

  • Total

Required return / cost of capital
FCFF terminal growth rate
Free cash flow forecast
Terminal value
ㅤPV breakdown
Enterprise value / PV of FCF
ㅤPlus / (Less): Net Debt
ㅤLess: preferred stock
ㅤLess: minority interest
Market cap
ㅤNumber of shares
Price per share

Latest Earnings Call Takeaways

Could not load earnings call summaries.

Boston Scientific Corporation — Financial Overview, Stock Price, Market Cap

Boston Scientific Corporation is a company. Founded in 1979. As of April 16, 2026, the company's market capitalization is $96021777475 with a current stock price of $64.61.